A few years ago, drug giant Bristol-Myers Squibb Co. announced it was retooling its strategy, meaning a drug it was developing for insomnia was probably headed for the sidelines. Vanda Pharmaceuticals ...
Modern science is just catching up to what folk and traditional healers have known since Homeric times. While lab-developed ...
This Nature Outlook is editorially independent, produced with financial support from Avadel. Miranda cannot remember a time in her life when she did not have insomnia. The 23 year old, who asked for ...
Instead of reaching for a pill, more people should switch to the recommended "first line" treatment for insomnia—the non-drug option. After exhaustive studies, the specially designed Cognitive ...
TOKYO, May 28, 2025 - (JCN Newswire) - - Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in ...
The "Insomnia: Opportunity Assessment and Forecast Update" report has been added to ResearchAndMarkets.com's offering. This report covers the 7MM and provides an Excel-based forecast model for the ...
A new clinical practice guideline is the first from the American Academy of Sleep Medicine to provide comprehensive, evidence-based analyses of individual agents commonly used in the treatment of ...
The U.S. Food and Drug Administration approved Belsomra (suvorexant) tablets for use as needed to treat insomnia. Belsomra is an orexin receptor antagonist and is the first approved drug of this type.
Investigational seltorexant improved symptoms of major depressive disorder (MDD) and insomnia in people with an inadequate response to antidepressants, a phase III trial indicated. By week 6, the ...
As far back as the 1800s, patients were prescribed medication for insomnia. While barbiturates were popularized in the early 1900s, they were soon replaced by benzodiazepines, such as Valium (1960s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results